WHWK Relative Valuation
WHWK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, WHWK is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for WHWK's competitors is 18.50, providing a benchmark for relative valuation. Whitehawk Therapeutics, Inc. Corp (WHWK) exhibits a P/S ratio of 2.37, which is -87.18% above the industry average. Given its robust revenue growth of 33.48%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
AAPL
Apple Inc
211.260
USD
-0.09%
NVDA
NVIDIA Corp
135.400
USD
+0.42%
AVGO
Broadcom Inc
228.610
USD
-1.73%
ORCL
Oracle Corp
160.490
USD
+0.68%
TSLA
Tesla Inc
349.980
USD
+2.09%
XOM
Exxon Mobil Corp
108.190
USD
-0.36%
WMT
Walmart Inc
98.240
USD
+1.96%
META
Meta Platforms Inc
640.340
USD
-0.55%
AMZN
Amazon.com Inc
205.590
USD
+0.20%
MSFT
Microsoft Corp
454.270
USD
+0.25%
FAQ
Is Whitehawk Therapeutics, Inc. (WHWK) currently overvalued or undervalued?
Whitehawk Therapeutics, Inc. (WHWK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.37 is considered Undervalued compared with the five-year average of 2.00. The fair price of Whitehawk Therapeutics, Inc. (WHWK) is between 3.64 to 4.86 according to relative valuation methord. Compared to the current price of 1.72 USD , Whitehawk Therapeutics, Inc. is Undervalued By 52.69% .
What is Whitehawk Therapeutics, Inc. (WHWK) fair value?
How does WHWK's valuation metrics compare to the industry average?
What is the current P/B ratio for Whitehawk Therapeutics, Inc. (WHWK) as of May 19 2025?
What is the current FCF Yield for Whitehawk Therapeutics, Inc. (WHWK) as of May 19 2025?
What is the current Forward P/E ratio for Whitehawk Therapeutics, Inc. (WHWK) as of May 19 2025?